Eioncell Co. Ltd. and Hallym University have reported new antibody-drug conjugates (ADCs) comprising an antibody targeting kita-kyushu lung cancer antigen 1 (KK-LC-1; CT83) linked to a cytotoxic drug potentially useful for the treatment of cancer.
Kyowa Kirin Co. Ltd. has identified new solute carrier family 15 member 4 (SLC15A4) inhibitors potentially useful for the treatment of autoimmune disease and lupus nephritis.
Gilead Sciences Inc. has described GTPase KRAS inhibitors, particularly wild-type KRAS, KRAS (G12C mutant), KRAS (G12D mutant) and/or KRAS (G12V mutant) inhibitors, found to be potentially useful for the treatment of cancer.
Work at Shouyao Holdings (Beijing) Co. Ltd. has led to the identification of new GTPase KRAS mutant inhibitors potentially useful for the treatment of cancer.
Cimplrx Co. Ltd. and Dong Wha Pharmaceutical Co. Ltd. have discovered new carboxamide derivatives acting as interleukin-1 receptor-associated kinase 4 (IRAK-4) and/or IRAK-1 inhibitors. As such, they are potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Genesis Molecular AI Inc. has synthesized new phosphatidylinositol 3-kinase α (PI3Kα) (mutant) inhibitors potentially useful for the treatment of cancer.
Tyra Biosciences Inc. has patented new pyrazolopyridine and imidazopyridine derivatives acting as fibroblast growth factor receptor 3 (FGFR3) inhibitors potentially useful for the treatment of cancer.
Shanghai Henlius Biologics Co. Ltd., Shanghai Henlius Biopharmaceutical Co. Ltd. and Shanghai Henlius Biotech Inc. have disclosed new antibody-drug conjugates comprising a monoclonal antibody targeting HER2 covalently linked to a camptothecin derivative potentially useful for the treatment of cancer.
RSS